PubRank

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Clinical Trial ID NCT05092412

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT05092412

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 52.99
2 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012 35.24
3 Signatures of mutational processes in human cancer. Nature 2013 21.63
4 PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008 19.24
5 Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002 12.39
6 MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014 10.49
7 Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007 8.94
8 The three Es of cancer immunoediting. Annu Rev Immunol 2004 8.20
9 Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008 8.17
10 Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2014 6.64
11 BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004 6.24
12 The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002 5.92
13 Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012 5.28
14 A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992 5.10
15 Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005 4.94
16 Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010 2.80
17 The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013 2.72
18 The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol 2011 2.69
19 Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992 1.87
20 Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012 1.43
21 Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol 2009 1.26
22 Small-cell lung cancer: treatment progress and prospects. Oncology (Williston Park) 1998 1.24
23 Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 2002 1.23
24 Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. Prog Biophys Mol Biol 2005 1.08
25 Treatment options for small cell lung cancer - do we have more choice? Br J Cancer 2010 1.07
26 Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res 2015 1.01
27 Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol 2016 0.93
28 A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. Clin Lung Cancer 2016 0.85
29 Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV. Cytotherapy 2008 0.78
30 Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates? Cancer Discov 2019 0.75
Next 100